Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating
I'm PortAI, I can summarize articles.
Analyst Joseph Pantginis of H.C. Wainwright has reiterated a Buy rating on Compass Therapeutics with a price target of $24.00. He cites the company's strong cash position of approximately $209 million, funding visibility into 2028, and a promising pipeline as key factors. Pantginis highlights the importance of 2026 for clinical data releases and trial initiations, particularly for tovecimig in metastatic colorectal cancer and CTX-8371 in Hodgkin lymphoma. The combination of these elements supports his positive outlook and Buy recommendation for the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments